Desmopressin acetate anhydrousProduct ingredient for Desmopressin

Desmopressin, also known as 1-deamino-8-D-arginine vasopressin (DDAVP), is a synthetic analogue of the natural posterior pituitary hormone arginine vasopressin (AVP) ^5,10. It was designed through two primary chemical modifications of the natural hormone: the deamination of 1-cysteine and the substitution of L-arginine with D-arginine at the 8th position ^1,5. These changes significantly enhance the drug's antidiuretic potency while virtually eliminating the vasopressor activity (vasoconstriction) associated with natural vasopressin ^1,5. Desmopressin is primarily indicated for the treatment of central diabetes insipidus, primary nocturnal enuresis (bedwetting) in children, and nocturia in adults ^5,9. Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors ^2,5.

First synthesized in the 1960s, desmopressin has remained a gold-standard therapy for water balance disorders due to its safety and long duration of action compared to natural AVP ^1,8. On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery system to minimize systemic water retention risks ^9,12. Despite its versatility, desmopressin carries a Boxed Warning regarding the risk of hyponatremia (critically low blood sodium levels), which can lead to seizures and death if fluid intake is not properly restricted ^9,11. It is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone ^5,10.